Key facts
- Kiffik Biomedical’s last known valuation is $185.0M (Oct 2023).
- It has raised $51.3M across 1 recorded rounds; the latest was Seed Round ($830K) in Sep 2021.
- Notable investors include Global Emerging Markets, West Midlands Health Tech Innovation Accelerator.
- Kiffik Biomedical has filed 2 Form Ds with the SEC, most recently Jun 2022 ($830K sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Kiffik Biomedical
Funding rounds
1 roundsAbout Kiffik Biomedical
Developer of an interstitial fluid technology designed to expand the understanding of diseases. The company's technology can be applied as a sampling and monitoring tool for drug research in preclinical and clinical trials as an alternative medium for bio-derivative production, enabling medical researchers and biopharmaceutical companies to find new possibilities in preventive medicine and empower patients to manage their health proactively.
- Sector
- Healthcare
- HQ
- Providence, RI, United States
- Founded
- 2018
- Employees
- 21
- Website
- kiffik.com/
- Ownership
- Privately Held (backing)
Kiffik Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kiffik Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kiffik Biomedical in its N-PORT filings yet. We sweep new filings monthly.